Franck Morschhauser

机构：Université de Lille, Centre Hospitalier Universitaire de Lille, Lille’s Cardiology Hospital, Hôpital Claude Huriez, Groupe de Recherche sur les formes Injectables et les Technologies Associées · ORCID：0000-0002-3714-9824

发表论文 921 篇 · 总被引 35381 次 · h-index 94

代表论文

• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 20)
• Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial (2025 · Annals of Oncology · 被引 4)
• Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3 (2025 · Blood · 被引 2)
• primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma (2025 · Blood · 被引 2)
• Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study (2026 · Blood Advances · 被引 1)
• FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma (2025 · Journal of Clinical Oncology · 被引 1)